IDP Pharma and BCN Peptides has entered a collaboration for the development of peptidomimetics. IDP Pharma will use its technology, IDP-Platform , to design peptidomimetics with target-specificity, intrinsic cell permeability properties and enhanced stability to target intra cellular proteins. BCN Peptide will optimize the synthesis and scale up the lead compounds.
IDP Pharma and BCN Peptides enter into a collaboration
news03 April 2017